News
NeurAxis Announces Over $8 Million in IB-Stim™ Revenue
CARMEL, Ind., Aug. 17, 2023 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced it has...
NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023
CARMEL, Ind., Aug. 15, 2023 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced a poster...
NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin
CARMEL, Ind., Aug. 10, 2023 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted...
NeurAxis Announces Pricing of Initial Public Offering
CARMEL, Ind., Aug. 09, 2023 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the...